BlueStone Venture Partners

BlueStone Venture Partners is a life science venture capital fund investing in entrepreneurial companies. The fund provides strategic capital and support to early-stage life science companies, primarily in Series A and Series B equity rounds. It focuses on medical devices, health IT, advanced materials, and molecular diagnostics. Mara Aspinall and Thomas Nickoloff launched the venture capital fund in Tucson, Arizona in 2018.

Mara Aspinall

Managing Director

Andrew More

Director

Past deals in Arizona

GT Medical Technologies

Series B in 2020
GT Medical Technologies, Inc. develops and manufactures a medical equipment for the treatment of brain tumors. The company offers GammaTile, a biocompatible device that combines conformable collagen matrix with brachytherapy (radiation) seeds. The company caters to the healthcare industry. GT Medical Technologies, Inc. was formerly known as Gammatile, Inc. The company was founded in 2017 and is based in Tempe, Arizona.

Pyx Health

Series A in 2020
Pyx Health is a mobile solution that reduces loneliness and social isolation. It connects members outside of the traditional care setting. By providing critical and timely interventions and addressing social determinants of health, it takes care of the members when they are most vulnerable, especially after a transition of care. Pyx Health offers Pyxir, an endearing chatbot personality that walks alongside your members in their health care journey. Affectionately referred to as ‘he’ by our members, Pyxir promotes healthy interaction within the app by building trusted companionship with its members 24/7. It was founded in 2017 and is headquartered in Tucson, Arizona.

Paradigm Diagnostics

Series B in 2019
Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.

GT Medical Technologies

Series A in 2019
GT Medical Technologies, Inc. develops and manufactures a medical equipment for the treatment of brain tumors. The company offers GammaTile, a biocompatible device that combines conformable collagen matrix with brachytherapy (radiation) seeds. The company caters to the healthcare industry. GT Medical Technologies, Inc. was formerly known as Gammatile, Inc. The company was founded in 2017 and is based in Tempe, Arizona.